Loading
This early TROP-2 antibody-drug conjugate was tested in a study that stopped before completing development.
NCT02122146 is terminated with 31 actual participants. The registry reports a business-related decision based on the overall results; this is a historical program, not a recruiting treatment opportunity.
Anti-TROP2 antibody-drug conjugate. Connects to TROP2.
1.PF-06664178's antibody arm binds TROP2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"PF-06664178" OR ABSTRACT:"PF-06664178") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PF-06664178, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/